发明名称 |
PHARMACEUTICAL COMPOSITIONS |
摘要 |
The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. |
申请公布号 |
WO2009095395(A3) |
申请公布日期 |
2010.03.18 |
申请号 |
WO2009EP50924 |
申请日期 |
2009.01.28 |
申请人 |
BIOVAIL LABORATORIES INTERNATIONAL SRL;WALSH, EDWIN;JACKSON, GRAHAM;OBEREGGER, WERNER;XIAOPIN, JIN |
发明人 |
WALSH, EDWIN;JACKSON, GRAHAM;OBEREGGER, WERNER;XIAOPIN, JIN |
分类号 |
A61K9/32;A61K9/36;A61K31/137;A61K31/343;A61K31/554 |
主分类号 |
A61K9/32 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|